Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treatment Strategy for Rifampin-Susceptible Tuberculosis.
Paton NI, Cousins C, Suresh C, Burhan E, Chew KL, Dalay VB, Lu Q, Kusmiati T, Balanag VM, Lee SL, Ruslami R, Pokharkar Y, Djaharuddin I, Sugiri JJR, Veto RS, Sekaggya-Wiltshire C, Avihingsanon A, Sarin R, Papineni P, Nunn AJ, Crook AM; TRUNCATE-TB Trial Team. Paton NI, et al. N Engl J Med. 2023 Mar 9;388(10):873-887. doi: 10.1056/NEJMoa2212537. Epub 2023 Feb 20. N Engl J Med. 2023. PMID: 36808186 Clinical Trial.
Importance of routine viral load monitoring: higher levels of resistance at ART failure in Uganda and Lesotho compared with Switzerland.
Bachmann N, von Braun A, Labhardt ND, Kadelka C, Günthard HF, Sekaggya-Wiltshire C, Castelnuovo B, Kambugu A, Lejone TI, Böni J, Yerly S, Perreau M, Klimkait T, Kouyos RD, Fehr J; Swiss HIV Cohort Study. Bachmann N, et al. J Antimicrob Chemother. 2019 Feb 1;74(2):468-472. doi: 10.1093/jac/dky436. J Antimicrob Chemother. 2019. PMID: 30476115
Prevalence of COVID-19 infection in TB clinics in Kampala, Uganda.
Otaalo B, Cevik M, Mwebesa E, Nabisere-Arinaitwe R, Zawedde-Muyanja S, Nampala J, Nanziri C, Alinaitwe L, Aber F, Bayigga J, Nankinga B, Laker E, Owarwo NC, Sabiiti W, Adakun S, Kirenga B, Turyahabwe S, Sloan DJ, Sekaggya-Wiltshire C. Otaalo B, et al. Int J Tuberc Lung Dis. 2023 Jun 1;27(6):481-483. doi: 10.5588/ijtld.23.0010. Int J Tuberc Lung Dis. 2023. PMID: 37231596 No abstract available.
A commentary on establishing a local centre of excellence for research and training in pharmacometrics: Lessons from the pharmacometrics Africa-Uganda chapter.
Najjemba L, Kawuma AN, Ojara FW, Obura B, Sekaggya-Wiltshire C, Arinaitwe W, Kikonyogo R, Mukonzo J, Pillai GC, Waitt C. Najjemba L, et al. Br J Clin Pharmacol. 2023 Sep;89(9):2658-2661. doi: 10.1111/bcp.15832. Epub 2023 Jul 7. Br J Clin Pharmacol. 2023. PMID: 37417585 Free PMC article. No abstract available.
Unexpectedly low drug exposures among Ugandan patients with TB and HIV receiving high-dose rifampicin.
Kengo A, Gausi K, Nabisere R, Musaazi J, Buzibye A, Omali D, Aarnoutse R, Lamorde M, Dooley KE, Sloan DJ, Sekaggya-Wiltshire C, Denti P. Kengo A, et al. Among authors: sekaggya wiltshire c. Antimicrob Agents Chemother. 2023 Nov 15;67(11):e0043123. doi: 10.1128/aac.00431-23. Epub 2023 Oct 18. Antimicrob Agents Chemother. 2023. PMID: 37850737 Free PMC article.
Dolutegravir pharmacokinetics in Ugandan patients with TB and HIV receiving standard- versus high-dose rifampicin.
Kengo A, Nabisere R, Gausi K, Musaazi J, Buzibye A, Omali D, Aarnoutse R, Lamorde M, Dooley KE, Sloan DJ, Denti P, Sekaggya-Wiltshire C. Kengo A, et al. Among authors: sekaggya wiltshire c. Antimicrob Agents Chemother. 2023 Nov 15;67(11):e0043023. doi: 10.1128/aac.00430-23. Epub 2023 Oct 18. Antimicrob Agents Chemother. 2023. PMID: 37850738 Free PMC article. Clinical Trial.
67 results